NOW APPROVED

The first and only FDA-approved treatment for PH-ILD1

TYVASO®SHIFTS
THE OUTLOOK FOR PH-ILD1

TYVASO is an inhaled prostacyclin mimetic indicated for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.1

The study establishing effectiveness predominately included patients with etiologies of1:

  • Idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF)
  • Combined pulmonary fibrosis and emphysema (CPFE) (25%)
  • WHO Group 3 connective tissue disease (22%)

Eligible patients
could pay as little
as a $5 co-pay
for each prescription

Learn about support
services for patients

Get in contact with a United Therapeutics Representative